drugset / Trial / NCT03850509
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
Phase 2
Terminated
3 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
IQVIA Pvt. Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the effects and safety of OPS-2071 (150, 300, or 600 mg twice a day \[BID\]) versus placebo, as add-on therapy in participants with Crohn's disease who show symptoms of active inflammation despite being on ongoing treatment.
Timeline
- Start
- 2020-02-25
- Primary completion
- 2020-05-22
- Completion
- 2020-05-22
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OPS-2071 | Small molecule | 150 mg | Oral |
| Subject | OPS-2071 | Small molecule | 300 mg | Oral |
| Subject | OPS-2071 | Small molecule | 600 mg | Oral |